This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Olinvacimab
DrugBank Accession Number
DB16265
Background

Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).

Type
Biotech
Groups
Investigational
Synonyms
  • Fully human monoclonal antibody targets vascular endothelial growth factor receptor 2
  • Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ttac-0001 heavy chain), disulfide with human monoclonal ttac-0001 light chain, dimer
  • Olinvacimab
  • Tanibirumab
External IDs
  • TTAC-0001

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
AVascular endothelial growth factor receptor 2
antibody
regulator
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Olinvacimab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Olinvacimab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Olinvacimab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olinvacimab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Olinvacimab.
AmivantamabThe risk or severity of adverse effects can be increased when Olinvacimab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Olinvacimab.
AnsuvimabThe risk or severity of adverse effects can be increased when Olinvacimab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Olinvacimab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Olinvacimab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
VFH55IZ5VI
CAS number
2095504-49-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentRecurrent Glioblastoma1
2RecruitingTreatmentMetastatic Breast Cancer, Triple Negative Breast Cancer1
2TerminatedTreatmentRecurrent Glioblastoma1
1Active Not RecruitingTreatmentRecurrent Glioblastoma1
1Active Not RecruitingTreatmentTriple Negative Breast Cancer1
1CompletedTreatmentCancer, Advanced / Metastatic Cancers1
1, 2Not Yet RecruitingTreatmentMetastatic Colorectal Cancer (CRC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antibody
Regulator
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and ...
Gene Name
KDR
Uniprot ID
P35968
Uniprot Name
Vascular endothelial growth factor receptor 2
Molecular Weight
151525.555 Da
References
  1. Tampellini M, Sonetto C, Scagliotti GV: Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs. 2016;25(5):507-20. doi: 10.1517/13543784.2016.1161754. Epub 2016 Mar 24. [Article]
  2. Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS: Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Invest New Drugs. 2017 Dec;35(6):782-790. doi: 10.1007/s10637-017-0463-y. Epub 2017 Apr 8. [Article]
  3. Kim J, Kim TE, Kim JA, Yun JH, Sohn S, Shim SR, Lee SH, Kim SJ: Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2014 Dec;30(10):847-53. doi: 10.1089/jop.2014.0021. [Article]
  4. Lee SH: Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res. 2011 Aug;34(8):1223-6. doi: 10.1007/s12272-011-0821-9. [Article]
  5. Kim DG, Jin Y, Jin J, Yang H, Joo KM, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH: Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. MAbs. 2015;7(6):1195-204. doi: 10.1080/19420862.2015.1086854. Epub 2015 Sep 1. [Article]

Drug created at December 15, 2020 18:17 / Updated at May 03, 2022 03:20